Assess whether to resubmit, meet, or pause the program (167867)

SITUATION Phase-3 protocol with endpoint-sensitivity issues arrived with a DSMB note on an imbalance that is not yet a signal. Regulatory-affairs lead in a safety team sitting on a new disproportionate signal still has an evidence gap on whether to resubmit, meet, or pause the program.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose To resubmit, meet,, Pause the program using phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal. The question on that file is whether to resubmit, meet, or pause the program.

HYPOTHESES TO TEST 1. Regulatory-affairs lead can defend To resubmit, meet, from phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge. 2. Regulatory-affairs lead cannot defend To resubmit, meet, from phase-3 protocol with endpoint-sensitivity issues; Pause the program is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal. 3. A DSMB note on an imbalance that is not yet a signal never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close to resubmit, meet, or. 4. Two facts in phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal conflict for regulatory-affairs lead; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for regulatory-affairs lead - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for regulatory-affairs lead in a safety team sitting on a new disproportionate signal